Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer: a Brazilian private payer perspective.
Anna Maria BuehlerGabriela CastilhoPierre-Alexandre DionneStephen StefaniPublished in: Therapeutic advances in medical oncology (2021)
As demonstrated by the cost-effectiveness dominance over palbociclib, ribociclib results in savings when used as first-line treatment in postmenopausal women with HR+/HER2- aBC, warranting incorporation in the private healthcare system.
Keyphrases
- metastatic breast cancer
- polycystic ovary syndrome
- early breast cancer
- locally advanced
- health insurance
- bone mineral density
- healthcare
- squamous cell carcinoma
- rectal cancer
- insulin resistance
- neoadjuvant chemotherapy
- breast cancer risk
- radiation therapy
- body composition
- open label
- clinical trial
- postmenopausal women
- type diabetes
- adipose tissue
- skeletal muscle